Venaxis executes contracts for Italy/Turkey APPY1 launch

Venaxis has executed two additional commercial development agreements as part of the initial phase of the European launch of CE-marked blood-based appendicitis test, APPY1. MOSS of Italy and SAVAS Medikal of Turkey have committed to market development activities within their respective territories and each have submitted initial stocking purchase orders for the APPY1 test/system. Venaxis entered a similar agreement with EMELCA Bioscience earlier in 2013, which covers Belgium, Luxembourg, and the Netherlands.

Venaxis has executed two additional commercial development agreements as part of the initial phase of the European launch of CE-marked blood-based appendicitis test, APPY1. MOSS of Italy and SAVAS Medikal of Turkey have committed to market development activities within their respective territories and each have submitted initial stocking purchase orders for the APPY1 test/system. Venaxis entered a similar agreement with EMELCA Bioscience earlier in 2013, which covers Belgium, Luxembourg, and the Netherlands.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare, Medical Devices
Geography: Italy, Italy, Turkey, Italy, Italy
×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.